XENE · Xenon Pharmaceuticals Inc.
$62.35
-1.88 (-2.93%)
At close · Aug 14
Market Cap
$6.04B
Shares
96.84M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ian Mortimer | President and Chief Executive Officer | $9,221,712 |
| Thomas Kelly | Chief Financial Officer | $7,238,664 |
| Darren Cline | Chief Commercial Officer | $4,048,214 |
| Christopher Kenney | Chief Medical Officer | $3,145,290 |
| Andrea DiFabio | Chief Legal Officer and Corporate Secretary | $3,062,790 |
| Sherry Aulin | Former Chief Financial Officer | $356,453 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ian Mortimer | President and Chief Executive Officer | $9,795,347 |
| Christopher Kenney | Chief Medical Officer | $4,196,940 |
| Sherry Aulin | Chief Financial Officer | $4,164,888 |
| Andrea DiFabio | Chief Legal Officer and Corporate Secretary | $4,104,490 |
| Christopher Von Seggern | Chief Commercial Officer | $4,090,590 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ian Mortimer | President and Chief Executive Officer | $10,117,829 |
| Christopher Kenney | Chief Medical Officer | $3,578,066 |
| Sherry Aulin | Chief Financial Officer | $3,523,045 |
| Christopher Von Seggern | Chief Commercial Officer | $2,764,805 |
| Robin Sherrington | Executive Vice President, Strategy and Innovation | $2,373,432 |
| Andrea DiFabio | Chief Legal Officer and Corporate Secretary | $1,721,162 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ian Mortimer | President and Chief Executive Officer | $9,228,604 |
| Andrea DiFabio | Chief Legal Officer and Corporate Secretary | $3,552,950 |
| Christopher Kenney | Chief Medical Officer | $3,263,857 |
| Sherry Aulin | Chief Financial Officer | $3,212,859 |
| Christopher Von Seggern | Chief Commercial Officer | $2,681,779 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Simon Pimstone | Executive Chair of the Board | $4,116,416 |
| Ian Mortimer | President and Chief Executive Officer | $3,894,997 |
| Sherry Aulin | Chief Financial Officer | $2,008,525 |
| Christopher Kenney | Chief Medical Officer | $1,935,409 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Simon Pimstone | Executive Chair of the Board | $2,941,911 |
| Ian Mortimer | President and Chief Executive Officer | $1,783,084 |
| Ernesto Aycardi | Chief Medical Officer | $1,106,739 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Simon Pimstone | Executive Chair of the Board | $2,612,720 |
| Ian Mortimer | President and Chief Executive Officer | $1,553,382 |
| Ernesto Aycardi | Chief Medical Officer | $1,072,977 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Simon Pimstone | Chief Executive Officer | $1,165,195 |
| Ian Mortimer | President and Chief Financial Officer | $922,681 |
| Ernesto Aycardi | Chief Medical Officer | $692,011 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Simon Pimstone | Chief Executive Officer | $1,469,198 |
| Corporate Secretary | — | $944,770 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Thomas (Tucker) Kelly | Chief Financial Officer | Appointed | 2025-10-16 |
| Sherry Aulin | Chief Financial Officer | Resigned | 2025-07-03 |
| Ian Mortimer | principal accounting officer | Appointed | 2025-07-03 |
| Ian Mortimer | interim Chief Financial Officer | Appointed | 2025-07-03 |
| Sherry Aulin | Chief Financial Officer | Resigned | 2025-02-27 |
| Justin Gover | director | Appointed | 2023-08-08 |
| Gillian Cannon | director | Appointed | 2023-08-08 |
| Gary Patou | director | Appointed | 2022-06-02 |
| Elizabeth Garofalo | director | Appointed | 2022-06-02 |
| Patrick Machado | director | Appointed | 2022-06-02 |
| Ian Mortimer | director | Appointed | 2022-06-02 |
| Steven Gannon | director | Appointed | 2022-06-02 |
| Dawn Svoronos | director | Appointed | 2022-06-02 |
| Mohammad Azab | director | Appointed | 2022-06-02 |
| Simon Pimstone | director | Appointed | 2022-06-02 |
Key facts
CIK
1582313
CUSIP
98420N105
13F (30d)
307 filings
301 filers
Visit website
Investor relations